Krsnaa Diagnostics Ltd
Krsnaa Diagnostics Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #5 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on Krsnaa Diagnostics Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue: INR 2,710 Mn, up 32% YoY from INR 2,060 Mn in Q2 FY26 (Page 6) - Q2 FY27 Retail Revenue: INR 235 Mn, up 35% YoY from INR 174 Mn in Q2 FY26 (Page 7) - Q2 FY27 Number of Tests Performed Q2 FY27 Financial Performance (Page 6): - Revenue: INR 2,710 Mn (32% YoY increase) - EBITDA: INR 719 Mn (20% YoY increase) - EBITDA Margin: 27% (down 2% from 29% YoY) - PAT: INR 246 Mn (3% YoY increase) - PAT Margin: 9% (down 3% from 12% YoY) - Details from Page 10: - EBITDA before CSR & ESOP for Q2 FY27: INR 719 Mn (27%) - EBITDA for Q2 FY27: INR 711 Mn (26%) - PAT for Q2 FY27: INR 246 Mn (9%) - Margin Outlook (Page 6): - Moderation in margins primarily due to upfront fixed costs in Rajasthan laboratories, equipment, manpower and logistics before full utilization.
From Krsnaa Diagnostics Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.
Revenue & Sales Performance
- Q2 FY27 Revenue: INR 2,710 Mn, up 32% YoY from INR 2,060 Mn in Q2 FY26 (Page 6)
- Q2 FY27 Retail Revenue: INR 235 Mn, up 35% YoY from INR 174 Mn in Q2 FY26 (Page 7)
- Q2 FY27 Number of Tests Performed: 30.3 million, up 85% YoY from 16.4 million in Q2 FY26 (Page 6)
2 more points from Krsnaa Diagnostics Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Krsnaa Diagnostics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital Work-in-Progress increased from INR 2,080.72 Mn (Mar 31, 2026) to INR 52.02 Mn (Sep 30, 2026), indicating ongoing projects.
- Mega CT/MRI Projects awarded in Maharashtra & Madhya Pradesh during 2023-24 (Company evolution page).
- Largest Integrated Pathology PPP Project awarded across Rajasthan state in 2025-26, indicating large-scale pathology capacity expansion.
- Strategic investment in Apulki – Oncology & Cardiac specialized diagnostics (2025-26).
- Entry into Specialized PET CT Diagnostics in PPP during 2026-27, signaling new capacity addition.
2 more points from Krsnaa Diagnostics Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Krsnaa Diagnostics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Krsnaa Diagnostics Ltd said on order book & pipeline — free account, 30 seconds.
Krsnaa Diagnostics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krsnaa Diagnost.'s management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Rainbow Child. (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
- Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
- Artemis Medicare (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
- Max Healthcare (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krsnaa Diagnostics Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krsnaa Diagnostics Ltd Q2 FY27 results?
Q2 FY27 Revenue: INR 2,710 Mn, up 32% YoY from INR 2,060 Mn in Q2 FY26 (Page 6) - Q2 FY27 Retail Revenue: INR 235 Mn, up 35% YoY from INR 174 Mn in Q2 FY26 (Page 7) - Q2 FY27 Number of Tests Performed Q2 FY27 Financial Performance (Page 6): - Revenue: INR 2,710 Mn (32% YoY increase) - EBITDA: INR 719 Mn (20% YoY increase) - EBITDA Margin: 27% (down 2% from 29% YoY) - PAT: INR 246 Mn (3% YoY increase) - PAT Margin: 9% (down 3% from 12% YoY) - Details from Page 10: - EBITDA before CSR & ESOP for Q2 FY27: INR 719 Mn (27%) - EBITDA for Q2 FY27: INR 711 Mn (26%) - PAT for Q2 FY27: INR 246 Mn (9%) - Margin Outlook (Page 6): - Moderation in margins primarily due to upfront fixed costs in Rajasthan laboratories, equipment, manpower and logistics before full utilization.
What is Krsnaa Diagnostics Ltd share price analysis?
Krsnaa Diagnostics Ltd currently shows a neutral. The stock trades at a P/E of 16.5 with a market cap of ₹1,634 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krsnaa Diagnostics Ltd planning capital expenditure?
Capital Work-in-Progress increased from INR 2,080.72 Mn (Mar 31, 2026) to INR 52.02 Mn (Sep 30, 2026), indicating ongoing projects.
Keep Krsnaa Diagnostics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.